{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:14:30Z","timestamp":1783498470411,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"DOI":"10.7759\/cureus.112249","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:25:12Z","timestamp":1783495512000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Six-Month Efficacy and Safety of Rituximab in Elderly and Younger Patients With Rheumatoid Arthritis: A Prospective Real-World Study"],"prefix":"10.7759","author":[{"given":"Ikram","family":"El Moubarik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"El Binoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Rostom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilham","family":"Benmarzouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghizlane","family":"Ghoullam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Zemrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"Amine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhor","family":"Zeghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.04.004","article-title":"Elderly-onset rheumatoid arthritis","volume":"77","author":"Soubrier M","year":"2010","unstructured":"Soubrier M, Mathieu S, Payet S, Dubost JJ, Ristori JM. Elderly-onset rheumatoid arthritis. Joint Bone Spine. 2010, 77:290-6. 10.1016\/j.jbspin.2010.04.004","journal-title":"Joint Bone Spine"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2006.12.006","article-title":"Rheumatic disease in the elderly: rheumatoid arthritis","volume":"33","author":"Tutuncu Z","year":"2007","unstructured":"Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am. 2007, 33:57-70. 10.1016\/j.rdc.2006.12.006","journal-title":"Rheum Dis Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2165\/11316740-000000000-00000","article-title":"Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy","volume":"26","author":"Villa-Blanco JI","year":"2009","unstructured":"Villa-Blanco JI, Calvo-Al\u00e9n J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging. 2009, 26:739-50. 10.2165\/11316740-000000000-00000","journal-title":"Drugs Aging"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22314","article-title":"Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry","volume":"66","author":"Payet S","year":"2014","unstructured":"Payet S, Soubrier M, Perrodeau E, et al.. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. Arthritis Care Res (Hoboken). 2014, 66:1289-95. 10.1002\/acr.22314","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.92","article-title":"The influence of ageing on the development and management of rheumatoid arthritis","volume":"9","author":"Boots AM","year":"2013","unstructured":"Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013, 9:604-13. 10.1038\/nrrheum.2013.92","journal-title":"Nat Rev Rheumatol"},{"key":"ref6","article-title":"Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis","volume":"33","author":"Bathon JM","year":"2006","unstructured":"Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006, 33:234-43.","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep291","article-title":"Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients","volume":"48","author":"K\u00f6ller MD","year":"2009","unstructured":"K\u00f6ller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford). 2009, 48:1575-80. 10.1093\/rheumatology\/kep291","journal-title":"Rheumatology (Oxford)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200623110-00001","article-title":"Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients","volume":"23","author":"Ornetti P","year":"2006","unstructured":"Ornetti P, Chevillotte H, Zerrak A, Maillefert JF. Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients. Drugs Aging. 2006, 23:855-60. 10.2165\/00002512-200623110-00001","journal-title":"Drugs Aging"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094730","article-title":"Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis","volume":"68","author":"Radovits BJ","year":"2009","unstructured":"Radovits BJ, Kievit W, Fransen J, van de Laar MA, Jansen TL, van Riel PL, Laan RF. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009, 68:1470-3. 10.1136\/ard.2008.094730","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards JC","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, et al.. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004, 350:2572-81. 10.1056\/NEJMoa032534","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60027-0","article-title":"Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial","volume":"379","author":"van Vollenhoven RF","year":"2012","unstructured":"van Vollenhoven RF, Geborek P, Forslind K, et al.. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012, 379:1712-20. 10.1016\/S0140-6736(12)60027-0","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00782-x","article-title":"Does older age have an impact on rituximab efficacy and safety? Results from the NOR-DMARD register","volume":"37","author":"Mielnik P","year":"2020","unstructured":"Mielnik P, Sexton J, Lie E, et al.. Does older age have an impact on rituximab efficacy and safety? Results from the NOR-DMARD register. Drugs Aging. 2020, 37:617-26. 10.1007\/s40266-020-00782-x","journal-title":"Drugs Aging"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/ar4521","article-title":"Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients","volume":"16","author":"Wendler J","year":"2014","unstructured":"Wendler J, Burmester GR, S\u00f6rensen H, et al.. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014, 16:R80. 10.1186\/ar4521","journal-title":"Arthritis Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha D","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al.. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010, 69:1580-8. 10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo ML","year":"1995","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:44-8. 10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen JS","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, et al.. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003, 42:244-57. 10.1093\/rheumatology\/keg072","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries JF","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980, 23:137-45. 10.1002\/art.1780230202","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.monrhu.2019.03.002","article-title":"Immunosuppressive therapies in the elderly [Article in French]","volume":"86","author":"Lahaye C","year":"2019","unstructured":"Lahaye C. Immunosuppressive therapies in the elderly [Article in French]. Rev Rhum Monogr. 2019, 86:222-7. 10.1016\/j.monrhu.2019.03.002","journal-title":"Rev Rhum Monogr"},{"key":"ref19","unstructured":"VIDAL. The leading reference website for healthcare professionals. https.\/\/www.vidal.fr\/."},{"key":"ref20","unstructured":"CRI practical guides. practical management of patients. http:\/\/www.cri-net.com\/fiches-pratiques-et-eSessions\/dernieres-mises-a-jour."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.10.012","article-title":"Overview of biologic treatments in the elderly","volume":"82","author":"Lahaye C","year":"2015","unstructured":"Lahaye C, Tatar Z, Dubost JJ, Soubrier M. Overview of biologic treatments in the elderly. Joint Bone Spine. 2015, 82:154-60. 10.1016\/j.jbspin.2014.10.012","journal-title":"Joint Bone Spine"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0341-2","article-title":"Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs","volume":"33","author":"Sugihara T","year":"2016","unstructured":"Sugihara T, Harigai M. Targeting low disease activity in elderly-onset rheumatoid arthritis: current and future roles of biological disease-modifying antirheumatic drugs. Drugs Aging. 2016, 33:97-107. 10.1007\/s40266-015-0341-2","journal-title":"Drugs Aging"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/art.22688","article-title":"Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study","volume":"57","author":"Genevay S","year":"2007","unstructured":"Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007, 57:679-85. 10.1002\/art.22688","journal-title":"Arthritis Rheum"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg JE","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, et al.. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010, 62:2625-32. 10.1002\/art.27555","journal-title":"Arthritis Rheum"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre","volume":"56","author":"Yusof MY","year":"2017","unstructured":"Yusof MY, Kabia A, Darby M, et al.. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. Rheumatology (Oxford). 2017, 56:1348-57. 10.1093\/rheumatology\/kex072","journal-title":"Rheumatology (Oxford)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","volume":"48","author":"Boleto G","year":"2018","unstructured":"Boleto G, Avouac J, Wipff J, et al.. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study. Semin Arthritis Rheum. 2018, 48:149-54. 10.1016\/j.semarthrit.2018.02.010","journal-title":"Semin Arthritis Rheum"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden","volume":"78","author":"Gr\u00f8n KL","year":"2019","unstructured":"Gr\u00f8n KL, Arkema EV, Glintborg B, et al.. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis. 2019, 78:320-7. 10.1136\/annrheumdis-2018-214326","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220178","article-title":"Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis","volume":"14","author":"Castagn\u00e9 B","year":"2019","unstructured":"Castagn\u00e9 B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PLoS ONE. 2019, 14:e0220178. 10.1371\/journal.pone.0220178","journal-title":"PLoS ONE"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505827-comparison-of-six-month-efficacy-and-safety-of-rituximab-in-elderly-and-younger-patients-with-rheumatoid-arthritis-a-prospective-real-world-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:25:23Z","timestamp":1783495523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505827-comparison-of-six-month-efficacy-and-safety-of-rituximab-in-elderly-and-younger-patients-with-rheumatoid-arthritis-a-prospective-real-world-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.112249","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}